Mayukh Sukhatme
President, Chief Investment Officer & DirectorDr. Mayukh Sukhatme, M.D., serves as Director of Roivant Sciences Ltd. since November 10, 2023 and is Chief Investment Officer and President since January 2021. He serves as Chief Investment Officer and President of Roivant Sciences, Inc. Dr. Sukhatme joined Roivant in 2015 and previously served as President of Roivant Pharma and as its Chief Business Officer. Dr. Sukhatme oversees the creation and support of biopharmaceutical companies in the Roivant family. Dr. Sukhatme served as Chief Business Officer at Roivant Sciences, Inc. Dr. Sukhatme served as Chairman of Urovant Sciences Ltd. since July 2018 until August 2018. He served as a Director of Cerecor, Inc. since July 11, 2014 until August 12, 2015. Dr. Sukhatme was a Partner of Apple Tree Partners. Dr. Sukhatme joined Roivant in 2015. Since June 2018, Dr. Sukhatme has served as Chief Business Officer and President of Roivant Pharma, a business unit of its controlling shareholder, RSL. From November 2016 to June 2018, Dr. Sukhatme served as RSI’s Chief Business Officer and from April 2015 to November 2016 as Senior Vice President, Business Development. Dr. Sukhatme was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development-stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. From 2000 to 2015, Dr. Sukhatme was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development-stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme received his M.D. from Harvard Medical School and Bachelor of Science degrees in Biology and Literature (Phi Beta Kappa) from MIT.
Positions
- Company NameRoivant Sciences Ltd.Stock CodeROIVPositionPresident, Chief Investment Officer & Director
